Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma

Shu Zheng, Ming-Yong Han, Zuo-Xiang Xiao, Jia-Ping Peng, Qi Dong

Shu Zheng, Ming-Yong Han, Zuo-Xiang Xiao, Jia-Ping Peng, Qi Dong, Cancer Institute, Zhejiang University, Hangzhou 310009, Zhejiang Province, China

Correspondence to: Professor Shu Zheng, Cancer Institute, Zhejiang University, Hangzhou 310009, Zhejiang Province, China

Telephone: +86-571-87214404 Fax: +86-571-87214404

Received: 2003-03-02 Accepted: 2003-04-01

Abstract

AIM: To clarify the association of vascular endothelial growth factor (VEGF) and microvascular density (MVD) expression with the angiogenesis and prognosis of colorectal cancer.

METHODS: A total of 97 cases of colorectal carcinomas were examined by immunohistochemical staining (SP method), using anti-VEGF and anti-factor CD34 monoclonal antibodies.

RESULTS: VEGF positive staining was obtained in 68 out of 97 cases (70.1 %), and observed mainly in the cytoplasm of tumor cells, and also frequently in stromal cells. VEGF expression was more intense in poorly differentiated adenocarcinoma in comparison with others, but there was no significant correlation between VEGF expression and age, sex and stage. A significant correlation was found between the MVD and grades, and there was no significant relationship between the MVD and age, sex, and stage. The MVD in the VEGF positive group (68 cases) was higher than that in the negative group. Upon multivariate analysis, the significant variables were stage, tumor grade and MVD; VEGF expression was not an independent prognostic factor.

CONCLUSION: The expression of VEGF has a significant correlation with MVD; MVD expression has prognostic value but VEGF has not in colon cancer.

Zheng S, Han MY, Xiao ZX, Peng JP, Dong Q. Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma. World J Gastroenterol 2003; 9(6): 1227-1230

http://www.wjgnet.com/1007-9327/9/1227.asp

INTRODUCTION

Angiogenesis is an essential process required for the growth and metastatic ability of solid tumors[1]. Some studies demonstrated that an increase in microvascular density (MVD) was found to be closely associated with the expression of vascular endothelial growth factor (VEGF), and that MVD and VEGF expression had a prognostic value in predicting metastasis of various malignant solid tumors[2,3]. Several studies have noted that the level of VEGF expression, a strong angiogenic factor, correlates with neovascularization and tumor progression in human breast and brain cancers and experimental tumor models[4,5]. In this study, we investigated the correlation of the VEGF and MVD in the tumor tissue of patients with colon cancer.

MATERIALS AND METHODS

Patients and tumor specimens

Tumor specimens from 97 patients resected for colorectal cancers, from the Second Affiliated Hospital of Zhejiang University (Hangzhou, China) from March 1993 to September 1995 were assessed. The age of the patients ranged from 36 to 74 years; 58 were male and 39 were female; average age, male 57.5 years old, female 61.5 years old. The patients were staged according to operation and pathological findings with UICC TNM classification: 9 (9.3 %) in stage I, 38 (39.2 %) in stage II, 32 (32.9 %) in stage III, and 18 (18.6) in stage IV.

Immunohistochemistry

Specimens were fixed in a 10 % formaldehyde solution and embedded in paraffin. Sections, 5 μm thick, were cut and mounted on glass slides. Immunohistochemical staining was performed using the avidin-biotin method. Staining for VEGF was performed using an anti-VEGF monoclonal antibody (MAb) (Calbiochem, Cambridge, UK). Staining for vascular endothelial cells was performed using an anti-CD34 MAb (DAKO, Copenhagen, Denmark). Briefly, formalin-fixed, paraffin-embedded 5 μm tissue sections were deparaffinised with xylene, dehydrated in ethanol and incubated with 3 % hydrogen peroxidase for 5 min. After washed with phosphate-buffered saline (PBS), tissue sections were incubated in 10 % normal bovine serum for 20 min, followed by an overnight incubation with anti-VEGF (1:50) antibody or anti-CD34 antibody (1:50). Biotinylated goat antimouse and antirabbit immunoglobulins were used as secondary antibodies. Peroxidase-conjugated avidin was used as a dilution of 1:500. Finally, 0.02 % diaminobenzidine and 1 % hydrogen peroxide in PBS were used as the substrate. Normal mouse IgG diluted to an equivalent protein concentration was used as a control in place of the primary antibody. Counterstaining was performed with haematoxylin.

Any single brown-stained cell that indicates an endothelial cell stained with CD34 was counted as a single vessel. Branching structures were counted as a single vessel, unless there was a break in the continuity of the structure. The stained sections were screened at 5 times magnification, to identify the areas of highest vascular density. After the area of highest neovascularization was identified, individual vessel counts were performed at ×200 magnification.

Evaluation of VEGF expression

For the evaluation of VEGF expression, immunostaining was classified in two groups, corresponding to the percentage of immunoreactive cells; the cut-off point to distinguish low from high VEGF expression was 25 % of positive carcinoma cells.

Statistical analysis

Statistical comparisons for significance were made with the Student’s t test and χ² test. Multivariate analysis was performed
RESULTS

VEGF expression

Positive staining was obtained in 68 out of 97 cases (70.1%) and a typical immunohistochemical staining is shown in Figure 1. VEGF immunoreactivity was observed mainly in the cytoplasm of tumor cells, and also frequently in stromal cells. The distribution of VEGF-staining was not continuous in the whole slide of the specimen. VEGF expression was more intense in poorly differentiated adenocarcinoma in comparison with other tumors ($P=0.014$), but there was no significant correlation between VEGF expression and age, sex and stage (Table 1).

Table 1 Relationship between clinicopathologic factors and VEGF expression ($n=97$)

| Variables                        | n (%) | VEGF expression |
|----------------------------------|-------|-----------------|
|                                 | +n(%) | - n(%) | $P$ value |
| Age                              |       |             |
| <45 years                        | 36    | 26(72.2)    | 10(27.8) |  |
| >45 years                        | 61    | 42(68.8)    | 19(31.2) |  |
| Sex                              |       |             |
| Male                             | 58    | 41(71.4)    | 17(25.9) |  |
| Female                           | 39    | 27(69.2)    | 12(31.1) |  |
| Different differentiation        |       |             |
| Well                             | 28    | 15(51.1)    | 13(48.9) |  |
| Moderate                         | 36    | 26(72.2)    | 10(27.8) |  |
| Poor                             | 33    | 27(81.8)    | 6(18.2)  | 0.014 |
| Stage                            |       |             |
| I                                | 9     | 7(77.8)     | 2(22.2)  |  |
| II                               | 38    | 27(71.1)    | 11(28.9) |  |
| III                              | 32    | 23(72.2)    | 9(27.8)  |  |
| IV                               | 18    | 11(61.5)    | 7(38.5)  |  |

$P<0.05$ vs Well differentiated group.

Microvascular density (MVD)

Any single brown-stained cell that indicates an endothelial cell stained with CD34 was counted as a single vessel (Figure 2). The median MVD was $187.6\pm17.3$. A significant correlation was found between the MVD and different grade (0.028), and there was no significant relationship between the MVD and age, sex, and stage (Table 2).

Table 2 Relationship between clinicopathologic factors and MVD ($n=97$)

| Variables                        | n (%) | MVD |
|----------------------------------|-------|-----|
|                                 | high MVD | low MVD | $P$ value |
| Age                              |       |     |
| <45 years                        | 36    | 20(55.6) | 16(44.4) |  |
| >45 years                        | 61    | 33(54.3) | 28(45.7) |  |
| Sex                              |       |     |
| Male                             | 58    | 32(55.2) | 26(44.8) |  |
| Female                           | 39    | 21(53.8) | 18(46.2) |  |
| Different differentiation        |       |     |
| Well                             | 28    | 12(42.9) | 16(57.1) |  |
| Moderate                         | 36    | 20(55.6) | 16(44.4) |  |
| Poor                             | 33    | 21(63.6) | 12(36.4) | 0.028 |
| Stage                            |       |     |
| I                                | 9     | 5(55.6)  | 4(44.4)  |  |
| II                               | 38    | 20(52.6) | 18(47.4) |  |
| III                              | 32    | 18(56.3) | 14(43.7) |  |
| IV                               | 18    | 10(55.6) | 8(44.4)  |  |

$P<0.05$ vs Well differentiated group.

Table 3 Relationship between MVD and VEGF expression

| Variables | MVD     |
|-----------|---------|
| VEGF (+)  | 213.4±12.8 |
| Expression (-) | 138.7±19.4 |

$P<0.05$ vs VEGF (-) group.

Table 4 Multivariate analysis of overall survival by Cox proportional hazards model

| Variable | Categories | Hazard ratio | SEM | $P$ value |
|----------|------------|--------------|-----|-----------|
| Age      | >45 years versus <45 years | 1.877 | 0.3796 |  |
| Sex      | Male versus female | 1.216 | 0.4071 |  |
| Differentiation | Poor versus others | 2.361 | 0.2438 | 0.0217 |
| Stage    | I, II versus III, IV | 2.973 | 0.1976 | 0.0012 |
| VEGF     | (+) versus (-) | 1.164 | 0.3874 |  |
| MVD      | >187.6 versus <187.6 | 2.526 | 0.2126 | 0.0314 |

$P<0.05$ vs Stage I, II group.

Association between VEGF expression and MVD

The MVD in the VEGF positive group was $213.4±12.8$, and that in the negative group was $138.7±19.4$. MVD in the VEGF expression group was higher than that in the VEGF negative group ($P=0.027$).
positive group was higher than that in the negative group ($P=0.027$) (Table 3).

### Multivariate analysis

Upon multivariate analysis of all patients, the significant variables were stage, tumor grade and MVD. Age, sex, VEGF expression were not independent prognostic factors (Table 4).

### DISCUSSION

Microvascularity is important in cancer growth and metastasis because it is involved in the transport of various nutrients to the tumor cells[1-3]. In this process of tumor growth and angiogenesis numerous angiogenic factors are involved. In recent years several of these factors have been identified[3-6]. One of the most important regulators of angiogenesis is VEGF. It induces the vascular stroma not only as a direct endothelial cell mitogen, but also as a potent mediator of microvessel permeability. This ability of VEGF to induce fenestrations on microvessels has been demonstrated in experimental tumors[7-10].

The VEGF is overexpressed in a variety of benign tissues and malignant human tumors. The expression of VEGF suggests that it plays a role in luminal secretion by increasing local vascular permeability[11]. In neuroendocrine tumors the high levels of VEGF expression could indicate a role for VEGF in the release of gastrointestinal hormones through the regulation of baseline permeability of the normal microcirculation[12]. The high level of VEGF expression in some malignant tumors, such as breast cancer, non-small cell lung cancer, bladder cancer and gastric cancer, is a characteristic feature of these tumors. Several studies have demonstrated that high microvessel density is a useful indicator for poor prognosis in these cancers[11-15].

CD34 antigen is expressed on immature human haematopoietic precursor cells and is progressively lost during maturation[16,17]. In normal resting tissues, anti-CD34 antibodies are predominantly neated with the luminal endothelial membrane, whereas the abluminal membrane is negative or only weakly positive. In contrast, significant staining of the endothelial abluminal microprocesses (EAM) has been found in tumor stroma[18]. It has been shown that CD34 is a marker for EAM during angiogenesis and the antigenicity of CD34 is preserved by freezing, or ethanol, and formalin fixation[19].

Microvessel density (MVD) and expression of VEGF act as a highly specific indicator of angiogenesis. Strong VEGF expression and high MVD are considered important parameters of tumor angiogenesis and related to poor survival probability in vulvar cancer patients[20,21]. In primary breast cancer, MVD and VEGF serve as a parameter for determining tumor biological, metastatic potential and prognosis[22]. VEGF is highly related to angiogenesis of gastric carcinoma and promotes growth, invasion and metastasis of gastric carcinoma, VEGF expression and MVD are predictors for the biological behavior of gastric carcinoma[23,24]. In primary liver cancer, besides tumor stage, satellite nodules and portal vein embolus, the MVD and VEGF expressions are also of prognostic significance[25].

Intense VEGF staining was found in the majority of advanced primary SCCs, lymph node metastases, and human SCCs in severe combined immunodeficient mice, where no dysplasia, CIS, or early SCCs showed intense immunostaining. Suggesting a role for VEGF in both clinical and experimental HNSSC[26,27]. By univariate analysis, VEGF expression and MVD in the biopsy specimens were significant predictors of bladder cancer recurrence. By multivariate analysis, only VEGF expression was an independent prognostic factor[27]. The metastatic potency of NPC tissue and the prognosis of the patients with NPC could be estimated by measuring MVD and the expression of VEGF in NPC tissue[28]. Previously it was demonstrated that in prostate tumors, angiogenesis measured as microvessel density (MVD) was associated with tumor stage as well as WHO grade and was an independent predictor of clinical outcome. Vascular endothelial growth factor (VEGF) is a major inducer of angiogenesis[29]. The relationship between VEGF expression and MVD in ovarian carcinoma suggests that in conjunction with the established clinicopathologic prognostic parameters of ovarian carcinoma, VEGF expression may enhance the predictability of patients at high risk for tumor progression who are potential candidates for further aggressive therapy[30]. But MVD in synovial sarcomas did not correlate with prognosis or VEGF expression, angiogenesis in synovial sarcoma might be controlled by angiogenesis activators other than VEGF[31]. In patients with invasive cervical cancer VEGF expression has no prognostic value in contrast with the MVD[32].

In this study, we found positive VEGF staining was obtained in 68 out of 97 cases (70.1 %). VEGF immunoreactivity was observed mainly in the cytoplasm of tumor cells, and also frequently in stromal cells. VEGF expression was more intense in poorly differentiated adenocarcinoma in comparison with other tumors, but there was no significant correlation between VEGF expression and age, sex and stage. A significant correlation was found between the MVD and different grade, and there was no significant relationship between the MVD and age, sex, and stage. MVD in the VEGF positive group was higher than that in the negative group. Upon multivariate analysis, the significant variables were stage, tumor grade and MVD; VEGF expression was not an independent prognostic factor. We conclude that MVD but not VEGF expression has prognostic value in colon cancer.

### REFERENCES

1. Folkman J, Tumor angiogenesis. Adv Cancer Res 1985; 43: 175-203
2. Decaussin M, Sartete H, Robert C, Moro D, Claraz C, Brambilla C, Brambilla E. Expression of vascular endothelial growth factor (VEGF) and its two receptors in non-small cell lung carcinoma (NSCLCs): correlation with angiogenesis and survival. J Pathol 1999; 188: 369-377
3. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442-447
4. Burian M, Quint C, Nuechter C. Angiogenic factors in laryngeal carcinomas: do they have prognostic relevance? Acta Otolaryngol 1999; 119: 289-292
5. Giatromanolaki A, Koukourakis MI, Stathopoulos GP, Kapsoritakis A, Pasparakis G, Kakolyris S, Sivridis E, Georgoulas V, Harris AL, Gatter KC. Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancer. Oncol Res 2000; 12: 33-41
6. Li Z, Shimada Y, Uchida S, Maeda M, Kawai A, Mori A, Itami A, Kano M, Watanabe G, Imaura M. TGF-alpha as well VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma. Int J Oncol 2000; 17: 453-460
7. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995; 108: 2369-2379
8. Fujimoto K, Hosotani R, Wada M, Lee JU, Koshiba T, Miyamoto Y, Tsuji S, Nakajima S, Doi R, Imamura M. Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur J Cancer 1996; 34: 1439-1447
9. Zhang L, Scott PA, Turley H, Leek R, Lewis CE, Gatter KC, Harris AL, Mackenzie IZ, Rees MC, Bicknell R. Validation of anti-vascular endothelial growth factor antibodies for immunohistochemical localization of VEGF in tissue sections: expression of VEGF in the human endometrium. J Pathol 1998; 185: 402-408
10. Terris B, Scozec JY, Rubbia L, Bregaud L, Pepper MS,
pression in hepatocellular carcinoma and surrounding liver: pos-
Yamamoto A, Nabika T, Nagasue N. Clinical significance of
cells and on endothelial abluminal microprocesses in the tumor
microvessel density and vascular endothelial growth factor ex-
Miyahara T, Ishigami S, Imamura M. In oesophageal squamous
neoplasia.

Schlingemann RO, Ogura Y, Traweek ST. Immunohistochemical study on tumor angiogenic factors in non-
vacular endothelial growth factor in digestive neuroendocrine
tumours. Histopathology 1998; 32: 133-138

Uchida S, Shimada Y, Watanabe G, Tanaka H, Shibagaki I, Miyahara T, Ishigami S, Imamura M. In oesophageal squamous
nasal-squamous cell carcinoma vascular endothelial growth factor is associated
p53 mutation, advanced stage and poor prognosis. Br J Can-
1998; 77: 1704-1709

de-Jong JS, van-Dier Pj, van-der-Valk P, Baak JP. Expression of
growth factors, growth-inhibiting factors, and their receptors in
vasive breast cancer. J Pathol 1998; 184: 53-57

Koomagi R, Volm M. Tissue-factor expression in human non-
small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int-J-Cancer
1998; 79: 19-22

Aikawa H, Takahashi H, Fujimura S, Sato M, Endo C, Sakurada
A, Kondo T, Tanita T, Matsumura Y, Ono S, Saito Y, Sagawa M. Immunohistochemical study on tumor angiogenic factors in non-
small cell lung cancer. Anticancer Res 1999; 19: 4305-4309

Neuchrist C, Quint C, PammerA, Burian M. Vascular endothel-
ial growth factor (VEGF) and microvessel density in squamous
cell carcinomas of the larynx: an immunohistochemical study. Acta Otolaryng 1999; 119: 732-738

Watt SM, Karhi K, Gatter K, Furley AJ, Katz FE, Healy LE, Altas
Lj, Bradley NJ, Sutherland DR, Levinsky R. Distribution and epitope analysis of the cell membrane glycoprotein associated with human hematopoietic progenitor cells. Leukemia 1987; 1: 417-426

El-Assal ON, Yamamoto M, Soda Y, Yamagchi M, Igarashi M, Yamamoto A, Nakiba T, Nagase N. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor expression in the angiogenesis of cirrhotic liver. Hepatology 1998; 27: 1554-1562

Schlingemann RO, Rietveld Fj, de Waal RM, Bradley NJ, Skene
Ai, Davies Aij, Greaves Mf, Denekamp j, Ruiter Dj. Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. Lab Invest 1990; 62: 690-696

Traweek ST, Kandalalf PL, Mehta P, Battifora H. The human hematopoietic progenitor cell antigen (CD34) in vascular neoplasia. Am J Clin Pathol 1991; 96: 25-31

Ogura Y, Sato K, Kato T, Saito K, Enomoto K. Immunohistoche-
mal analysis of expression of angiogenic factors and tumor an-
giogenesis in superficial bladder cancer. Nippon Hinyokika Gakkai
Zassi 1998; 89: 529-537

Obermaier A, KohlbergerP, Bancher Todesca D, Tempfer C, Slutz
G, Leodolter S, Reinhaller C, Kainz C, Breitenecker G, Giltsch G. Influence of microvessel density and vascular permeability fac-
tor/vascular endothelial growth factor expression on prognosis in
vascular cancer. Gynecol Oncol 1996: 63: 204-209

Jiang X, Huang X, Li J. The correlation between tumor angiogen-
esis and lymph node metastasis in primary breast carcinoma. Zhonghua Waike Zazhi 1997; 35: 583-585

Lu M, Jiang Y, Wang R. The relationship of vascular endothelial growth factor and angiogenesis to the progression of gastric
carcinoma. Zhonghua Bingliuxe Zazi 1998; 27: 278-281

Xia J, Yang B, Ye S. Clinico-pathological significance of microvessel density and VEGF expression in primary liver cancer.
Zhonghua Zhongliu Zazhi 1998; 20: 440-442

Ikeguchi M, Oka S, Saito H, Kondo A, Tsujitani S, Maeta M,
Kaibara N. The expression of vascular endothelial growth factor and proliferative activity of cancer cells in gastric cancer. Langenbecks Arch Surg 1999; 384: 264-270

Sauter ER, Neibit M, Watson JC, Klein-Szanto A, Litwin S, Herlyn
M. Vascular endothelial growth factor is a marker of tumor inva-
sion and metastasis in squamous cell carcinoma of the head and
neck. Clin Cancer Res 1999; 5: 775-782

Inoue K, Slaton JW, Karashima T, Yoshikawa C, Shuin T,
Sweeney P, Millikan R, Dinney CP. The prognostic value of an-
giogenesis factor expression for predicting recurrence and meta-
stasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 2000; 6: 4866-4873

Guang WH, Sunagawa M, Jie En L, Shimada S, Gang Z, Tksheyi
Kosugi T. The relationship between microvessel density, the exp-
ression of vascular endothelial growth factor, and the extension of
nasopharyngeal carcinoma. Laryngoscope 2000; 110: 2066-2069

Strohmeyer D, Rossing C, Bauerfeind A, Kauffmann O, Schlechte
H, Bartsch, G, Loening S. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate
cancer. Prostate 2000; 45: 216-224

Shen GH, Ghazizadeh M, Kawanami O, Shimizu H, Jin E, Araki
T, Sugisaki Y. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Can-
cer 2000; 83: 196-203

Kawachi S, Fukuda T, Tsuneyoshi M. Angiogenesis does not
correlate with prognosis or expression of vascular endothelial
growth factor in synovial sarcomas. Oncol Rep 1999; 6: 959-964

Tjalma W, Weyler J, Weyn B, Van-Mark E, Van-Daele A, Van-
Dam P, Goovaerts G, Buytaert P. The association between vascu-
lar endothelial growth factor, microvessel density and clinic
pathological features in invasive cervical cancer. Eur J Obstet
Gynecol Reprod Biol 2000; 92: 251-257

Edited by Zhang JZ